Department of Cardiology and Vascular Diseases, Pontchaillou University Hospital, Center for Clinical Investigation 804, University of Rennes 1, Signal and Image Treatment laboratory (LTSI), National Institute of Health and Medical Research U1099, Rennes, France.
Department of Cardiology, University Hospital of Dijon-Burgundy, 5 boulevard Jeanne d'Arc, 21000 Dijon, France.
Eur Heart J. 2018 Jun 7;39(22):2090-2102. doi: 10.1093/eurheartj/ehy127.
To derive and validate a readily useable risk score to identify patients at high-risk of in-hospital ST-segment elevation myocardial infarction (STEMI)-related cardiogenic shock (CS).
In all, 6838 patients without CS on admission and treated by primary percutaneous coronary intervention (pPCI), included in the Observatoire Régional Breton sur l'Infarctus (ORBI), served as a derivation cohort, and 2208 patients included in the obseRvatoire des Infarctus de Côte-d'Or (RICO) constituted the external validation cohort. Stepwise multivariable logistic regression was used to build the score. Eleven variables were independently associated with the development of in-hospital CS: age >70 years, prior stroke/transient ischaemic attack, cardiac arrest upon admission, anterior STEMI, first medical contact-to-pPCI delay >90 min, Killip class, heart rate >90/min, a combination of systolic blood pressure <125 mmHg and pulse pressure <45 mmHg, glycaemia >10 mmol/L, culprit lesion of the left main coronary artery, and post-pPCI thrombolysis in myocardial infarction flow grade <3. The score derived from these variables allowed the classification of patients into four risk categories: low (0-7), low-to-intermediate (8-10), intermediate-to-high (11-12), and high (≥13). Observed in-hospital CS rates were 1.3%, 6.6%, 11.7%, and 31.8%, across the four risk categories, respectively. Validation in the RICO cohort demonstrated in-hospital CS rates of 3.1% (score 0-7), 10.6% (score 8-10), 18.1% (score 11-12), and 34.1% (score ≥13). The score demonstrated high discrimination (c-statistic of 0.84 in the derivation cohort, 0.80 in the validation cohort) and adequate calibration in both cohorts.
The ORBI risk score provides a readily useable and efficient tool to identify patients at high-risk of developing CS during hospitalization following STEMI, which may aid in further risk-stratification and thus potentially facilitate pre-emptive clinical decision making.
旨在建立并验证一个易于使用的风险评分模型,以识别发生院内 ST 段抬高型心肌梗死(STEMI)相关心原性休克(CS)的高危患者。
在所有纳入研究的患者中,共有 6838 例患者在入院时无 CS,接受直接经皮冠状动脉介入治疗(pPCI)治疗,他们来自 Observatoire Régional Breton sur l'Infarctus(ORBI)队列,作为推导队列,另外 2208 例患者来自 obseRvatoire des Infarctus de Côte-d'Or(RICO)队列,作为外部验证队列。采用逐步多变量逻辑回归建立评分模型。有 11 个变量与院内 CS 的发生独立相关:年龄>70 岁、既往卒中和短暂性脑缺血发作、入院时发生心搏骤停、前壁 STEMI、首次医疗接触至 pPCI 时间>90min、Killip 分级、心率>90 次/分、收缩压<125mmHg 与脉压<45mmHg 同时存在、血糖>10mmol/L、罪犯病变为左主干冠状动脉病变、pPCI 后心肌梗死溶栓治疗血流分级<3 级。基于这些变量,建立的评分模型可以将患者分为四个风险类别:低危(0-7 分)、低危到中危(8-10 分)、中危到高危(11-12 分)和高危(≥13 分)。在推导队列中,四个风险类别的院内 CS 发生率分别为 1.3%、6.6%、11.7%和 31.8%。在 RICO 队列中验证的院内 CS 发生率分别为 3.1%(评分 0-7 分)、10.6%(评分 8-10 分)、18.1%(评分 11-12 分)和 34.1%(评分≥13 分)。该评分模型具有较高的区分度(推导队列的 C 统计量为 0.84,验证队列为 0.80),且在两个队列中均具有较好的校准度。
ORBI 风险评分提供了一个易于使用和有效的工具,可以识别 STEMI 后住院期间发生 CS 的高危患者,有助于进一步进行风险分层,从而可能有助于预先做出临床决策。